Ovarian reserve testing: essential preparation and clinical markers

We hear versions of those questions every week, and the underlying uncertainty is the same: how do I read these numbers, and what do they actually tell me about my chances? The honest answer is more layered than the lab report suggests, and far more reassuring than the internet would have you believe, once you understand what each marker measures and how we use the three of them together.

Ovarian reserve testing is a set of three clinical tools that estimate the size of your remaining oocyte pool and predict how your ovaries are likely to respond to fertility medication. They are not fertility verdicts. They're a map, and like any map, they're most useful when you know which scale you're reading and which terrain they're actually charting.

The role of AMH in assessing ovarian potential

Anti-Müllerian hormone (AMH) is a protein secreted by the granulosa cells surrounding small, early-stage follicles — the ones quietly waiting in your ovaries before they've been recruited into a particular cycle. Because those follicles are continuously present and the hormone they release doesn't fluctuate dramatically across the menstrual cycle, AMH can be measured on any day. No fasting, no timing around ovulation, no rescheduling the work meeting.

What that single number tells us is the relative size of your recruitable follicle pool — in other words, how many eggs your ovaries could plausibly be coaxed into producing if we stimulated them. A higher AMH generally reflects a larger pool; a lower AMH suggests fewer recruitable follicles waiting in reserve. Chromosomal integrity of the oocytes inside those follicles lives in a different clinical conversation, one shaped far more by age than by any hormone level.

Ovarian reserve tests tell us about quantity, not quality — and that distinction shapes everything about how we interpret your numbers.

A practical note we share with patients who are comparing AMH values across different clinics: assays aren't perfectly standardized, so absolute numbers can shift slightly between laboratories. If you're tracking a trend over time, try to stay on the same platform when you can, and let your clinician interpret any single value in the context of your age, your AFC, and your goals.

Timing and protocols for basal FSH and estradiol testing

Follicle-stimulating hormone (FSH) behaves differently from AMH, and that's where timing matters. FSH rises and falls across the cycle in response to ovarian feedback, so a meaningful "baseline" reading has to be drawn during the early follicular phase — typically cycle days 2 through 4, with day 1 counted as the first day of full flow.

We pair that draw with estradiol (E2) for a reason that often surprises patients. A "normal" FSH can mask a struggling ovary when estradiol is quietly elevated, because estrogen suppresses FSH at the pituitary. Reading them together prevents that false reassurance. If your FSH comes back elevated, or if estradiol is high enough to artificially push FSH into the normal range, the picture shifts — and we want to know that before planning a stimulation cycle.

One historical test you may encounter in older literature is the clomiphene citrate challenge test. The American Society for Reproductive Medicine (ASRM) Practice Committee has advised against its routine use in favor of these simpler, non-dynamic tests — so if a clinician proposes CCCT today, it's worth asking why and whether an AMH plus AFC would give equivalent information with less medication exposure.

Transvaginal ultrasound and the significance of antral follicle counts

The third leg of ovarian reserve assessment is a transvaginal ultrasound performed in the early follicular phase, often on the same visit as your blood draw. We count the antral follicles — small, fluid-filled structures measuring between 2 and 10 mm in diameter — across both ovaries. That total is your antral follicle count (AFC), and it's the most direct real-time look we have at the cohort of follicles your ovaries are about to recruit.

AFC correlates closely with how you'll respond to gonadotropin stimulation. An AFC below roughly 4 to 7 total follicles across both ovaries raises concern for diminished ovarian reserve and predicts a lower oocyte yield in IVF. An AFC of 15 or more signals the opposite — a robust pool, but also a heads-up that we need to plan your stimulation carefully to reduce the risk of ovarian hyperstimulation syndrome (OHSS).

A few practical things to know before your scan:

• The procedure is the same transvaginal ultrasound used for many gynecologic evaluations; emptying your bladder beforehand is usually the only preparation.
• We're counting follicles, and the report will give you a total — often with a per-ovary breakdown.
• A single low AFC at one moment doesn't lock in your trajectory; we treat it as one data point alongside AMH and your age.

Interpreting clinical markers for IVF stimulation planning

Putting the three together is where the clinical value compounds. When we sit down to plan an IVF protocol, we're triangulating, not hunting for a single threshold that grants or denies treatment.

A young patient with a low AMH and a low AFC will be counseled about an anticipated lower oocyte yield per cycle, and we may discuss modified mild stimulation, dual-trigger protocols, or banking embryos across multiple cycles. A patient with a high AMH and an AFC above 15 gets a different conversation: how to dose gonadotropins carefully, when to use a GnRH antagonist protocol, and whether a freeze-all strategy makes sense to keep her safe from OHSS. Same three tests, very different plans.

ASRM guidance is explicit on this point: a low AMH or a low AFC should be used to counsel patients about expected yield, never as a standalone criterion to refuse treatment. The same logic applies to borderline or "low-normal" results. Your numbers inform your plan; they don't define your ceiling.

A low AMH value is counseling information, not a closed door — and the ASRM reinforces that distinction explicitly in its clinical guidance.

If you've been told your results are "too low" to try IVF without a full workup, that's a fair question to push back on. Ask how the team is interpreting your AMH and AFC together, what stimulation approach they're proposing, and what realistic yield they expect per cycle. That conversation is part of the standard of care, and it's the one where your test results start doing their actual job.

Addressing misconceptions regarding egg quality and natural fertility

Two myths come up so often in our clinic that they deserve direct attention.

The first is the assumption that ovarian reserve tests measure egg quality. They don't. Egg quality refers to the chromosomal integrity of the oocyte, which is most strongly tied to age and to meiotic spindle function — neither of which AMH, FSH, or AFC can assess. A 28-year-old with a low AMH has meaningfully better odds of producing a chromosomally normal egg than a 40-year-old with a high AMH, because age remains the dominant variable for aneuploidy risk. Reserve tests simply weren't built to answer the quality question, and no amount of repeat testing will change that.

The second is the leap from "low reserve" to "I can't get pregnant naturally." Ovarian reserve markers tell us about the pool of eggs remaining, not about whether ovulation, fertilization, or implantation will work in any given cycle. Plenty of patients with low AMH conceive without assistance — sometimes quickly, sometimes after a longer wait that has more to do with sperm, tubes, timing, or endometrial receptivity than with their reserve number. The tests are most predictive of response to stimulation, which is why they matter so much in ART planning and so much less in everyday conception conversations.

A related confusion involves hormonal contraception. Combined pills, the patch, the ring, and some progestin methods can suppress AMH readings, sometimes for months after discontinuation. If you're on hormonal contraception when the test is ordered, your clinician may suggest waiting through several cycles off the method before drawing AMH — or interpreting the result knowing it's likely an underestimate. There's no universal timeline here because individual recovery varies, so timing of the draw should be a shared decision between you and your team.

What to bring to your next conversation

A useful way to walk into this appointment is to know what each test measures, when it should be drawn, and how the three results speak to each other. AMH offers a flexible, any-day snapshot of your follicle pool. FSH and estradiol need to be drawn early in your cycle, ideally together. AFC gives us a real-time ultrasound count of small follicles across both ovaries. Together, they predict how your ovaries will respond to stimulation, set safety guardrails around OHSS, and inform — but do not decide — your treatment plan.

The next question worth asking your doctor is whether your results have been reviewed as a set rather than in isolation, and what your individualized stimulation strategy looks like in light of them. That's the conversation where ovarian reserve testing actually starts working for you.